EP. 2 The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC
EP. 4 Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
EP. 5 Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
November 19th, 2026FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal CancerThe FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.Read more
November 19th, 2026Revisit Every OncLive On Air Episode From October 2026In case you missed any, read a recap of the episodes of OncLive On Air that aired in October 2026. Read more
November 17th, 2026Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.Read more
November 16th, 2026Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic CancerThe European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.Read more
November 16th, 2026Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRCOnvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.Read more
November 12th, 2026GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.Read more
November 8th, 2026Five Under 5: Top Oncology Videos for the Week of 11/1The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.Read more